PRF Technologies Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Efraim Cohen-Arazi
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 65 Yigal Alon Street Tel Aviv TA Israel 6745442
- IPO Date
- Sep 1, 2020
- CIK
- 0001801834
- Website
- painreform.com
- Similar Companies
- Business
- PainReform Ltd. (Nasdaq: PRFX) is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics to provide extended-release drug delivery for post-surgical pain relief and advancing AI-driven solar analytics through its DeepSolar platform; it develops proprietary oil-based, viscous solutions deposited directly into surgical wounds, including PRF-110 based on ropivacaine for localized postoperative analgesia targeting bunionectomy and other procedures, OcuRing-K from its majority stake in LayerBio Inc., a sustained-release intraocular ring delivering ketorolac for dropless pain and inflammation control following cataract surgery in a $9 billion global market, and DeepSolar's SaaS solutions such as MyDeepSolar consumer app for residential solar optimization, DeepSolar Predict forecasting tool, and smart energy management platforms for enterprises. The company, founded in 2007 and headquartered at 65 Yigal Alon Street in Tel Aviv, Israel, operates primarily in the healthcare and renewable energy sectors, serving surgical patients, ophthalmology markets, and solar energy customers across North America, Europe, and other regions through clinical trials, R&D, and commercial pilots. In recent developments, PainReform completed the acquisition of DeepSolar in March 2025 to expand into AI-driven clean energy analytics with partnerships like a 92MW commercial agreement with Econergy in Romania and acceptance into the NVIDIA Connect Program; it acquired a majority equity interest in LayerBio in August 2025, adding the OcuRing-K platform to its non-opioid pain management pipeline; and continues R&D on PRF-110 after partially positive Phase 3 efficacy signals in the first 48 postoperative hours despite not meeting the primary endpoint, while reducing net loss to $2.3 million for the six months ended June 30, 2025, from $12.8 million year-over-year with $3.5 million in cash.
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026
PRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets
PRF Technologies' DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
Why Is PRF Tech Stock Falling On Monday?
PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
Short Interest in PainReform Ltd. (NASDAQ:PRFX) Drops By 13.3%
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements
PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base
PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy
PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push
PainReform Ltd. Changes Name to PRF Technologies Ltd.
PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies
PainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial Comparison
PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market
BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week